Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701).

Nichole LaPointe,Nick Hertle,Shu Chi Hsu,James Kellis,Nita King,Joshua Littrell,Quyen Nguyen,Jianan Ren,Marko Srdanov,Vaishali Tanna,Sanchit Thakrar,Tianxun Zhao,Robert Saiz,Nathalie Le Bail,Anne-Laure Bauchet,Anne-Sophie Lacoste-Bourgeacq,Mustapha Chadjaa,Paul Ferrari

Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701).

2021

Nichole LaPointe
Nick Hertle
Shu Chi Hsu
James Kellis
Nita King
Joshua Littrell
Quyen Nguyen
Jianan Ren
Marko Srdanov
Vaishali Tanna
Sanchit Thakrar
Tianxun Zhao
Robert Saiz
Nathalie Le Bail
Anne-Laure Bauchet
Anne-Sophie Lacoste-Bourgeacq
Mustapha Chadjaa
Paul Ferrari

e21030Background: Despite recent advances in non-small cell lung cancer (NSCLC) treatment, a need remains for treatment options at disease progression. Tusamitamab ravtansine (SAR408701) is an anti...

Keywords:

treatment options
Immunohistochemistry
Cancer research
Medicine
non small cell
disease progression
Antibody-drug conjugate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations